Bosentan is an endothelin (ET) receptor antagonist of ET-A (Ki = 4.7 nM) and ET-B (Ki = 95 nM).

Macitentan is an antagonist of endothelin receptor A (ETA) with IC50 of 0.5 nM. It is developed for treatment of pulmonary arterial hypertension (PAH).